6809-52-5
CAS 6809-52-5
6809-52-5 (CAS 6809-52-5) is a pharmaceutical compound with 1 bioactivity target and 164 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | AC50 | 5353.95 nM | 2 | - |
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Hepatic function abnormal | 68 | 120.13 | 10019670 |
| Platelet count decreased | 94 | 104.257 | 10035528 |
| Interstitial lung disease | 62 | 78.149 | 10022611 |
| Anaemia | 119 | 75.438 | 10002034 |
| Renal impairment | 67 | 67.859 | 10062237 |
| White blood cell count decreased | 68 | 58.388 | 10047942 |
| Upper respiratory tract inflammation | 17 | 54.609 | 10049590 |
| Liver disorder | 39 | 46.233 | 10024670 |
| Drug ineffective | 17 | 43.42 | 10013709 |
| Hyperuricaemia | 19 | 42.224 | 10020903 |
| Neutrophil count decreased | 40 | 41.868 | 10029366 |
| Fatigue | 11 | 40.981 | 10016256 |
| Pyrexia | 118 | 40.237 | 10037660 |
| Cerebral haemorrhage | 32 | 40.123 | 10008111 |
| Drug eruption | 28 | 39.631 | 10013687 |
| Disseminated intravascular coagulation | 25 | 37.029 | 10013442 |
| Enterocolitis | 18 | 36.417 | 10014893 |
| Cerebral infarction | 26 | 33.853 | 10008118 |
| Osteonecrosis of jaw | 25 | 31.58 | 10064658 |
| Gamma-glutamyltransferase increased | 27 | 31.552 | 10017693 |
| Erythema multiforme | 17 | 30.968 | 10015218 |
| Decreased appetite | 70 | 29.595 | 10061428 |
| Cardiac failure | 42 | 27.712 | 10007554 |
| Malignant neoplasm progression | 40 | 26.85 | 10051398 |
| C-reactive protein increased | 38 | 26.669 | 10006825 |
| Colon cancer | 15 | 25.615 | 10009944 |
| Gastric ulcer haemorrhage | 12 | 24.707 | 10017826 |
| Pneumonia | 101 | 24.421 | 10035664 |
| Alanine aminotransferase increased | 40 | 24.123 | 10001551 |
| Haemoglobin decreased | 48 | 23.309 | 10018884 |
| Drug-induced liver injury | 24 | 22.14 | 10072268 |
| Aspartate aminotransferase increased | 35 | 21.903 | 10003481 |
| Spinal compression fracture | 14 | 21.585 | 10041541 |
| Pain | 14 | 21.58 | 10033371 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is 6809-52-5 used for in pharmaceutical contexts?
6809-52-5 (CAS 6809-52-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for 6809-52-5?
6809-52-5 has 164 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Hepatic function abnormal, Platelet count decreased, Interstitial lung disease, Anaemia, Renal impairment. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is 6809-52-5 also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Teprenone with EU status "permitted".
What clinical phase is 6809-52-5 in?
No phase 1-4 clinical development badge is rendered for 6809-52-5 because the matched compound identifier rows do not contain a max-phase value.